|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US8153689||NABRIVA||Pleuromutilin derivatives for the treatment of diseases mediated by microbes|| |
(4 years from now)
|US8071643||NABRIVA||Pleuromutilin derivatives for the treatment of diseases mediated by microbes|| |
(5 years from now)
|US9120727||NABRIVA||Process for the preparation of pleuromutilins|| |
(7 years from now)
Xenleta is owned by Nabriva.
Xenleta contains Lefamulin Acetate.
Xenleta has a total of 3 drug patents out of which 0 drug patents have expired.
Xenleta was authorised for market use on 19 August, 2019.
Xenleta is available in solution;intravenous dosage forms.
Drug patent challenges can be filed against Xenleta from 2028-08-19.
The generics of Xenleta are possible to be released after 23 May, 2031.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Chemical Entity Exclusivity (NCE)||Aug 19, 2024|
|Generating Antibiotic Incentives Now (GAIN)||Aug 19, 2029|
NCE-1 date: 2028-08-19
Market Authorisation Date: 19 August, 2019
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic